[Linde Q2 2026 Earnings Call] Record $9.3B Sales, 10% EPS Growth Mask Lincare Margin Squeeze, Prompting Strategic Review

Linde’s second quarter was a study in contrasts. Sales and earnings set records, the project backlog swelled to an all-time high, and end markets from electronics to aerospace hummed. Yet the mood on Friday’s earnings call was unmistakably one of dissatisfaction, as a persistent margin squeeze in the company’s U.S. home care business forced management to tell investors it is actively evaluating whether that business still deserves a place in the portfolio.

“We are not satisfied with our margin performance for this quarter,” CEO Sanjiv Lamba said in his opening remarks, setting a frank tone that would echo through the Q&A session. While consolidated sales rose 9% to $9.3 billion and adjusted earnings per share climbed 10% to $4.50, operating margins contracted 60 basis points year-over-year to 29.5%. Even after stripping out the dilutive effect of cost pass-throughs, the margin decline was 30 basis points—a shortfall that Lamba and CFO Matt White attributed chiefly to Lincare, the U.S. home healthcare business that Linde has been pruning for years but which still consumes roughly 23% of the Americas healthcare revenue.

Financial snapshot

Metric	Q2 2026	YoY Change
Sales	$9.3 billion	+9%
Adjusted EPS	$4.50	+10%
Operating Margin	29.5%	-60 bps (-30 bps ex-cost pass-through)
Underlying Sales Growth	+4%	split evenly between volume (+2%) and price (+2%)
Project Backlog (sale of gas)	$8.1 billion	record, +$1 billion sequentially

“The Americas business, ex the U.S. home care or Lincare business would be up 20 basis points on margin,” Lamba told BNP Paribas analyst Laurent Favre. That math reveals the extent of the drag: without Lincare, the core industrial gas engine in the Americas was expanding profitability, buoyed by double-digit hard goods sales and a nascent manufacturing recovery in the United States.

White later quantified the Lincare penalty for JPMorgan’s Jeff Zekauskas, whose model had assumed a $30 million quarterly headwind. “It’s probably higher,” White said. “You could probably say 30% higher than that number.” That implies a roughly $40 million impact in the quarter alone, or around $160 million annualized—a sum that makes the “strategic options” review newly urgent.

Lincare under the microscope

The challenges at Lincare are not new. The business, which provides at-home respiratory and oxygen therapies, has been grappling with labor cost inflation and changes in reimbursement policies for several years. A new management team installed last year has been pruning the portfolio, but Lamba admitted those actions “simply has not been enough to overcome the continued headwinds.”

“We continue to evaluate the strategic fit of this U.S. home care business within Linde, both in part and as a whole, while remaining focused on improving its performance and ensuring it earns its place in the portfolio,” he said. That language—evaluating “in part and as a whole”—signals that a divestiture of all or portions of Lincare is on the table, a prospect that analysts received positively. Lamba stressed that any decision would be made with “diligence” and that aggressive operational actions are already underway, with sequential margin improvement expected as soon as the third quarter.

A record backlog and an electronics bonanza

Away from the Lincare overhang, Linde’s growth story is firing on all cylinders. The company secured a $1 billion electronics contract in the U.S. during the quarter to supply advanced-node semiconductor fabs, pushing the sale-of-gas backlog to a record $8.1 billion. Even after accounting for more than 20 project startups expected for the remainder of 2026—representing about $1.3 billion in investments—Lamba said the backlog should end the year “with an eight handle,” meaning above $8 billion.

“The electronics pipeline is looking healthy,” he said. “I see bulk of those projects out of the U.S., but see strong pipelines in Taiwan and Korea as well, and some in China.” Not included in the backlog are two wins by Linde’s Taiwan joint venture, which will invest approximately $800 million to build, own, and operate air separation units and hydrogen production facilities to supply a new semiconductor fab and advanced packaging facilities.

Electronics was the company’s fastest-growing end market in the quarter, with sales up 18% year-over-year, driven by AI-related hardware demand and fab expansions. Manufacturing also posted robust growth, with aerospace accounting for more than one-third of the increase. U.S. hard goods sales—cylinders, welding equipment, and related consumables—rose at a double-digit clip, a leading indicator that Lamba called “a good signal of manufacturing recovery.”

Guidance: cautious optimism, no macro bet

For the third quarter, Linde guided EPS of $4.45 to $4.55, representing 6–8% growth. The full-year EPS range was lifted at the bottom end by a dime to $17.70–$17.90, implying 8–9% growth. Crucially, both figures assume no economic improvement at the midpoint.

“While base volumes showed some recovery in the second quarter, we’d like a few more quarters under our belt before incorporating this trend into future guides,” White said. “Therefore, we’re leaving the back half guidance assumption the same as before.” He added that a series of cost actions are being accumulated this quarter to get ahead of inflation, particularly in regions where price growth is not being matched by volume.

Helium: navigating Hormuz, eyeing normalization

The Strait of Hormuz conflict continues to roil helium supply chains. Lamba praised his team for managing the disruption, signing new long-term contracts and raising prices, but acknowledged that dislocation costs are still dilutive to margins. “Any change in the Strait of Hormuz and the fact that we restart helium production back in Qatar… I think will have a lasting impact for the rest of the year,” he said, noting that normalization likely won’t occur until early 2027. Goldman Sachs analyst Duffy Fischer pressed on whether helium could become a tailwind next year; Lamba replied that the market should normalize, but “the complexity of volume and price mix will play a role.”

Beyond helium, the Middle East crisis has dampened industrial activity in hydrocarbon-dependent Asian economies like India, parts of ASEAN, and Australia. “Once those issues are resolved, you will see that normalization happen fairly quickly,” Lamba said. For now, the impact is visible but manageable, and does not alter the company’s long-term investment thesis for the region.

Analysts zero in on the 8–12% algorithm

Deutsche Bank’s David Begleiter asked whether Linde needs macroeconomic help to hit double-digit EPS growth next year. Lamba was clear: “We’re not looking for macro. As long as macro is not taking away from that, you should expect us to look at that 8% to 12% range.” He cautioned that it’s too early for formal 2027 guidance, but pointed to the record backlog, the electronics pipeline, possible helium normalization, and productivity actions as self-help levers that keep the target within reach regardless of the economic backdrop.

Space: a billion-dollar opportunity still on track

Linde’s bet on commercial space is advancing. Lamba reiterated the company’s view that the market represents a $1 billion-plus opportunity by 2030, adding that once it reaches sufficient scale, it will be broken out as a separate end market. Capital expenditure guidance was raised partly to accommodate base investments for space customers. Both sale-of-gas and sale-of-plant models are in play, with some customers showing interest in vertically integrating atmospheric gas production while continuing to rely on Linde for hydrogen.

The path forward

Linde’s core industrial gas business is performing well, and its project backlog offers visibility into high-return growth for years. But the Lincare anchor has become too heavy to ignore. The upcoming strategic decision—whether to fix, sell, or break up the unit—will likely be the most consequential move for the portfolio in 2026. In the meantime, investors can expect cost actions, sequential margin improvement, and a leadership team that is no longer willing to tolerate underperformance from what was once a reliable profit center.